Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal Cancer

Sponsor: National Cancer Center, Korea
Study ID: NCT00506623
Phase: PHASE2
Status: Unknown

Conditions

Neoadjuvant Therapy
Rectal Neoplasm

Eligibility Criteria

Sex: ALL
Age: 18 Years - 75 Years
Healthy Volunteers: Not accepted

Interventions

Capecitabine, Irinotecan — DRUG

Study Details

This study is to evaluate the pathologic complete response rate to pre-operative concurrent chemoradiotherapy with capecitabine plus irinotecan in resectable rectal cancer

Key Dates

Start date: Jul 31, 2004
Status verified: Jul 2007
Completion: Dec 31, 2008

Study Design

Enrollment: 48 participants (actual)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Primary Outcome Measure

Pathologic stage Tumor regression grade [ Time Frame: After operation ]